AHA blog: 340B Analysis Wrong and Irresponsible

Jul 24, 2023 - 04:04 PM
340B pic

A Modern Healthcare analysis of 340B hospitals “should be viewed with the derision it deserves,” writes AHA General Counsel and Secretary Melinda Hatton. “It is decidedly not independent … These hospitals deserve to be repaid fully as recompense for that illegal policy. End of story.” READ MORE

Related News Articles

Headline
Senate HELP Committee holds hearing on growth, impact of 340B
The Senate Committee on Health, Education, Labor and Pensions Oct. 23 held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on…
Headline
Rhode Island district court denies drug company efforts to block state’s 340B contract pharmacy law 
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
AHA says HRSA vastly underestimates costs 340B Rebate Pilot Program will inflict on hospitals, urges agency to delay implementation
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
District court denies preliminary injunctions by drug companies in challenges to Maine’s 340B contract pharmacy law
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Headline
AHA comments on CY 2026 OPPS proposed rule
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
Appeals court upholds lower court denial of AbbVie’s preliminary injunction, preserving Mississippi 340B contract pharmacy law
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…